India to Brazil: Pembrolizumab Export Trade Route

The India to Brazil Pembrolizumab corridor is one of India's established pharmaceutical export routes, with 103 shipments documented worth a combined $860.1K USD. The route is dominated by GEMINI HEALTHWORLD LLP, which alone accounts for roughly 25% of all export value, reflecting the consolidated nature of India's pembrolizumab manufacturing sector.

Across 14 active suppliers, the average shipment value stands at $8.4K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 79% of all shipments, consistent with pembrolizumab's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 33 days port-to-port. The route has recorded an annual growth rate of 27.5%, placing it at rank #12 among India's top pembrolizumab export destinations globally.

On the import side, key buyers of Indian pembrolizumab in Brazil include TO THE ORDER, AS PER INVOICE, F AGAINST PROFORMA INVOICE and 27 others. TO THE ORDER is the single largest importer with 27 shipments valued at $218.6K USD.

India's pembrolizumab exports to Brazil are driven primarily by a handful of large-scale manufacturers. GEMINI HEALTHWORLD LLP with 26 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 14 active exporters signals a competitive but concentrated market — buyers in Brazil benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — GEMINI HEALTHWORLD LLP, VAMA LIFECARE PRIVATE LIMITED, SPECIALITY MEDICINES LIMITED — together account for 63% of total trade value on this route. The average shipment value of $8.4K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as contain medicines harmless pharmaceuticals product pembrolizumab 100mg/4ml injection(k eytruda) and harmless medicine keytruda 100mg/4ml injection pembrolizumab 1 vial, suggesting that buyers in Brazil tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, TO THE ORDER is the largest importer with 27 shipments worth $218.6K USD — representing 25% of all pembrolizumab imports from India on this route. A total of 30 buyers are active on this corridor.